Belviq, Halaven still modest for Eisai as Aricept plunges
This article was originally published in Scrip
Executive Summary
Generic competition continued to eat away at Eisai's one-time blockbuster Aricept (donepezil) in the fiscal first half, when global sales of the Alzheimer's disease treatment fell by 15% to JPY45.3bn ($460m).